Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...

Part of the partners' plan is to use Plex's AI to identify potential new uses for existing treatments that can be used to ...

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

The conference runs from April 2-4, 2025. Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations ...

The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique ...

Charles Schwab Investment Management Inc. increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) ...